Posted on September 16, 2025

Enrolment Update

On September 3, 2025, Dr. Christopher Johnson at the Parkview Packnett Family Cancer Institute enrolled the first U.S. participant into the trial, a major milestone for the study. To date, five patients have been successfully enrolled across two sites: Parkview Cancer Institute in Indiana, USA, and Hospital de Clínicas de Porto Alegre in Brazil. Additional clinical sites across Canada, the U.S., and internationally are nearing activation, and the team looks forward to continued participant enrollment throughout the summer.